Director James Gordon Liddy of Hepion Pharmaceuticals, Inc. filed a statement of changes in beneficial ownership on October 27, 2026, reporting the acquisition of 510,000 stock options on October 23, 2026.

Key Highlights

  • Reporting Person: James Gordon Liddy, a director of Hepion Pharmaceuticals, Inc. (OTC:HEPA)
  • Transaction Date: October 23, 2026, with the filing submitted on October 27, 2026
  • Options Acquired: 510,000 stock options (transaction code A) at an exercise price of $0.14 per share
  • Vesting Schedule: 42,500 options vest in equal amounts monthly over 12 months from the date of grant
  • Expiration Date: October 23, 2036, giving the options a ten-year term
  • Price Paid: $0 for the derivative securities at time of grant
  • Resulting Ownership: 809,000 stock options beneficially owned following the reported transaction, held directly

Liddy's Stock Option Grant at Hepion Pharmaceuticals

According to the filing, Hepion Pharmaceuticals, Inc. (OTC:HEPA), a pharmaceutical company incorporated and operating in the United States with offices at 22 West St., Suite 1B, Red Bank, New Jersey 07701, granted director James Gordon Liddy 510,000 stock options on October 23, 2026. The options carry an exercise price of $0.14 per share and are exercisable into shares of common stock. The filing lists the price of the derivative security at grant as $0, meaning no direct cost was paid by Liddy to receive the options at the time of award.

The filing notes, per the explanation of responses, that "42,500 options vest in equal amounts monthly over 12 months from date of grant." The options are set to expire on October 23, 2036, establishing a ten-year window from the grant date during which they may be exercised, subject to the vesting schedule. Following this transaction, Liddy's total directly held derivative securities beneficial ownership stands at 809,000 stock options, as reported in Table II of the disclosure. The filing was made by one reporting person and is not identified as an amendment to a prior filing.

What Was Disclosed

The filing disclosed that director James Gordon Liddy acquired 510,000 stock options in Hepion Pharmaceuticals, Inc. on October 23, 2026, at an exercise price of $0.14, vesting monthly over 12 months, with a resulting total beneficial ownership of 809,000 options.